Stemline Therapeutics, Inc. (STML)

Oncology Corporate Profile

Stock Performance

5.5000
0.1700

HQ Location

750 Lexington Avenue, 11th Floor
New York, NY 10022

Company Description

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk in a variety of cancer types. Stemline is currently developing two clinical-stage product candidates, SL-401 and SL-701.

Website: http://www.stemline.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
SL-401interleukin-3 receptor (IL-3R)Acute Myelogenous Leukemia (AML)II
SL-701immunotherapyGlioblastoma Multiforme (GBM)I

Source


http://www.stemline.com

Recent News Headlines

STEMLINE SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Stemline Therapeutics, Inc. – (STML)

3/25/2017 02:05 am

[Business Wire] - Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until April 4, 2017 to file lead plaintiff applications in a securities class action lawsuit against Stemline Therapeutics, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Stemline Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – STML

3/24/2017 09:01 pm

[GlobeNewswire] - NEW YORK, March 24, 2017-- Pomerantz LLP announces that a class action lawsuit has been filed against Stemline Therapeutics, Inc. and certain of its officers. The class action, filed in United States District ...

INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

3/24/2017 03:02 pm

[Accesswire] - IRVINE, CA / ACCESSWIRE / March 24, 2017 / Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Stemline Therapeutics, Inc. ("Stemline" or the "Company") ...

DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline: April 4, 2017

3/24/2017 02:03 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 24, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Stemline Therapeutics, Inc. ("Stemline" or ...

Blog Coverage Stemline Announces Completion of Enrollment for the Stage 3 SL-401 Pivotal Trial

3/24/2017 12:01 pm

[Accesswire] - Upcoming AWS Coverage on Jazz Pharmaceuticals Post-Earnings Results LONDON, UK / ACCESSWIRE / March 24, 2017 / Active Wall St. blog coverage looks at the headline from Stemline Therapeutics, Inc. (NASDAQ: ...

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Investors In Stemline Therapeutics, Inc. Of Imminent Lead Plaintiff Deadline

3/24/2017 01:04 am

[PR Newswire] - NEW YORK, March 23, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Stemline Therapeutics, Inc. ("Stemline" or the "Company") (STML) of the April 4, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers. The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Stemline stock or options between January 6, 2017 and February 1, 2017 (the "Class Period"). The case, Soileau v. Stemline Therapeutics, Inc. et al, No. 17-cv-01003 was filed on February 10, 2017, and has been assigned to Judge Paul A. Crotty. The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose the extent of the negative side effects of SL-401, its trial drug therapy directed to the interleukin-3 receptor present on a range of hematologic cancers.

Stemline Therapeutics Announces Completion of Enrollment in Stage 3 of the SL-401 Pivotal Trial in BPDCN

3/23/2017 11:00 am

[GlobeNewswire] - NEW YORK, March 23, 2017-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet medical need, announced today that enrollment ...

INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm

3/22/2017 03:01 pm

[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / March 22, 2017 / Lundin Law PC , a shareholder rights firm, announces the filing of a class action lawsuit against Stemline Therapeutics, Inc. ("Stemline" or the ...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc.

3/22/2017 01:05 pm

[Business Wire] - The following statement is being issued by Levi & Korsinsky, LLP:

SHAREHOLDER NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

3/21/2017 02:04 pm

[Accesswire] - IRVINE, CA / ACCESSWIRE / March 21, 2017 / Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Stemline Therapeutics, Inc. ("Stemline" or the "Company") ...

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline: April 4, 2017

3/20/2017 02:02 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 20, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Stemline Therapeutics, Inc. ("Stemline" or ...

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm

3/18/2017 05:01 pm

[GlobeNewswire] - LOS ANGELES, March 18, 2017-- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Stemline Therapeutics, Inc. concerning possible violations of federal securities ...

Stemline Investors Reminder: Hagens Berman Reminds Investors in Stemline Therapeutics of the April 4, 2017 Lead Plaintiff Deadline

3/17/2017 08:00 pm

[GlobeNewswire] - SAN FRANCISCO, March 17, 2017-- Hagens Berman Sobol Shapiro LLP reminds investors in Stemline Therapeutics, Inc. of the April 4, 2017 Lead Plaintiff deadline in the pending securities class action.. If ...

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Stemline Therapeutics, Inc. To Contact The Firm Before Lead Plaintiff Deadline

3/17/2017 07:03 pm

[GlobeNewswire] - NEW YORK, March 17, 2017-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Stemline Therapeutics, Inc. of the April 4, 2017 deadline to seek the role of lead plaintiff ...

SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm

3/17/2017 03:01 pm

[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / March 17, 2017 / Lundin Law PC , a shareholder rights firm, announces the filing of a class action lawsuit against Stemline Therapeutics, Inc. ("Stemline" or the ...

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc.

3/17/2017 03:00 pm

[Business Wire] - The following statement is being issued by Levi & Korsinsky, LLP:

Shareholder Deadline Reminder (STML): Johnson & Weaver, LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics and Encourages Investors with Losses to Contact the Firm

3/17/2017 01:04 pm

[PR Newswire] - SAN DIEGO, March 17, 2017 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP (J&W) announces the filing of a class action lawsuit on behalf of purchasers of Stemline Therapeutics, Inc. (NASDAQ: ...

Stemline Therapeutics Reports Fourth Quarter 2016 Financial Results

3/16/2017 11:02 pm

[GlobeNewswire] - NEW YORK, March 16, 2017-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet medical need, announced today financial ...

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

3/15/2017 03:01 pm

[Accesswire] - IRVINE, CA / ACCESSWIRE / March 15, 2017 / Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Stemline Therapeutics, Inc. ("Stemline" or the "Company") ...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline: April 4, 2017

3/15/2017 02:02 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 15, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Stemline Therapeutics, Inc. ("Stemline" or ...